Glycoengineered Pichia-Based Expression of Monoclonal Antibodies

  • Dongxing Zha
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 988)

Abstract

Currently, mammalian cells are the most commonly used hosts for the production of therapeutic monoclonal antibodies (mAbs). These hosts not only secrete mAbs with properly assembled two heavy and two light chains but also deliver mAbs with a glycosylation profile that is compatible with administration into humans. GlycoFi, a wholly owned subsidiary of Merck & Co., Inc., humanized the Pichia glycosylation pathway which allows it to express glycoproteins with a human-like glycan profile. This offers an alternative mAb production platform similar to mammalian hosts and in some cases it even provides more homogenous product and better efficacy, such as enhanced effector function. This chapter describes a protocol for using glycoengineered Pichia to produce full-length mAbs. It covers a broad spectrum of mAb expression technologies in yeast including expression vector construction, yeast transformation, high-throughput strain selection to fermentation, and antibody purification.

Key words

Glycoengineered Pichia Monoclonal antibody Glycosylation profile High-throughput screening FACS Fermentation and purification 

References

  1. 1.
    Li J, Zhu Z (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 31:1198–1207PubMedCrossRefGoogle Scholar
  2. 2.
    Anon (2010) Deal watch BMS acquires rights for IL-6 inhibitor. Nat Rev Drug Discov 9:10–10Google Scholar
  3. 3.
    Li HJ, Sethuraman N, Stadheim TA, Zha DX, Prinz B, Ballew N, Bobrowicz P et al (2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24:210–215PubMedCrossRefGoogle Scholar
  4. 4.
    Komarova TV, Kosorukov VS, Frolova OY, Petrunia IV, Skrypnik KA, Gleba YY, Dorokhov YL (2011) Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth. PLoS One 6(3):e17541PubMedCrossRefGoogle Scholar
  5. 5.
    Grohs BM, Niu Y, Veldhuis LJ, Trabelsi S, Garabagi F, Hassell JA, McLean MD, Hall JC (2010) Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. J Agric Food Chem 58:10056–10063PubMedCrossRefGoogle Scholar
  6. 6.
    Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N (2009) A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol 27(15 Suppl)Google Scholar
  7. 7.
    Zhang N, Liu L, Dan DC, Cummings NR, Cukan M, Jiang Y et al (2011) Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3:289–298PubMedCrossRefGoogle Scholar
  8. 8.
    Potgieter TI, Cukan M, Drummond JE, Houston-Cummings NR, Jiang YW, Li F et al (2009) Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 139:318–325PubMedCrossRefGoogle Scholar
  9. 9.
    Orchard MG, Neuss JC, Galley CM, Carr A, Porter DW, Smith P, Scopes DI et al (2004) Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg Med Chem Lett 14:3975–3978PubMedCrossRefGoogle Scholar
  10. 10.
    Lin S, Shen Z, Zha D, Sharkey N, Prinz B, Hamilton S et al (2010) Selection of Pichia pastoris strains expressing recombinant immunoglobulin G by cell surface labeling. J Immunol Methods 358:66–74PubMedCrossRefGoogle Scholar
  11. 11.
    Barnard GC, Kull AR, Sharkey NS, Shaikh SS, Rittenhour AM, Burnina I et al (2010) High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies. J Ind Microbiol Biotechnol 37:961–971PubMedCrossRefGoogle Scholar
  12. 12.
    Jiang Y, Li F, Zha D, Potgieter TI, Mitchell T, Moore R et al (2011) Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris. Protein Expr Purif 76:7–14PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Dongxing Zha
    • 1
  1. 1.GlycoFi Inc., Merck and CoLebanonUSA

Personalised recommendations